Buy LLY Stock At $820?

The pharmaceutical sector is experiencing a rerating as investors anticipate less severe impacts from tariffs and drug price cuts, with Eli Lilly (LLY) highlighted as a particularly attractive opportunity. Despite a 13% weekly rally, LLY is noted for its "monopoly-like" high margins, robust revenue growth (36.8% LTM), and strong profitability (43.0% operating margin LTM), while trading at a 37% discount compared to a year ago. However, the article cautions that LLY, despite strong fundamentals, is susceptible to significant declines during broader market downturns, having experienced substantial drops in past crises.

Analysis

The pharmaceutical sector is experiencing a broad rerating as investor concerns regarding the impact of tariffs and drug price cuts have eased. Within this context, Eli Lilly (LLY) is highlighted as a compelling opportunity, having already rallied 13% this week. The company's financial profile is characterized by strong fundamental performance, including last-twelve-months (LTM) revenue growth of 36.8%, which outpaces its three-year average of 23.4%. Profitability is also robust, with an LTM operating margin of 43.0% and an operating cash flow margin of 20.5%, both showing improvement over their respective three-year averages. This financial strength is attributed to significant pricing power, leading to predictable cash flows. Despite its recent stock price appreciation, LLY is presented as being undervalued, trading at a price-to-sales multiple of 13.9, a 37% discount compared to its valuation one year ago. However, the analysis is tempered with a significant risk consideration: LLY has historically shown high sensitivity to systemic market shocks, with drawdowns of 51% during the Global Financial Crisis and between 18% and 22% in more recent market downturns, indicating that its strong fundamentals do not insulate it from broad market volatility.

Key Decisions for Investors

• Given Eli Lilly's combination of strong revenue growth, high operating margins, and a valuation that is at a 37% discount to the previous year, investors could interpret the current environment as a favorable opportunity despite the recent 13% stock price increase.
• Investors should be aware of the stock's significant historical volatility during broad market downturns and consider implementing risk management strategies, as past declines have ranged from 18% to over 50% during crisis periods.
• It is crucial to monitor the sustainability of LLY's high margins and pricing power, as these are identified as the core drivers of its 'monopoly-like' profitability and are fundamental to the investment thesis.
• While the stock's fundamentals are strong, its performance is also tied to sector-wide sentiment, so investors should continue to track regulatory news concerning tariffs and drug pricing which initially catalyzed the sector's rerating.